290 related articles for article (PubMed ID: 37882914)
21. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
Medeiros da Frota Ribeiro C; Riva-Posse P
Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
[TBL] [Abstract][Full Text] [Related]
22. Treatment-resistant depression: are animal models of depression fit for purpose?
Willner P; Belzung C
Psychopharmacology (Berl); 2015 Oct; 232(19):3473-95. PubMed ID: 26289353
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
[TBL] [Abstract][Full Text] [Related]
24. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
Edwards SJ; Hamilton V; Nherera L; Trevor N
Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
[TBL] [Abstract][Full Text] [Related]
25. Management of Treatment-Resistant Depression: Challenges and Strategies.
Voineskos D; Daskalakis ZJ; Blumberger DM
Neuropsychiatr Dis Treat; 2020; 16():221-234. PubMed ID: 32021216
[TBL] [Abstract][Full Text] [Related]
26. Association of thalamic hyperactivity with treatment-resistant depression and poor response in early treatment for major depression: a resting-state fMRI study using fractional amplitude of low-frequency fluctuations.
Yamamura T; Okamoto Y; Okada G; Takaishi Y; Takamura M; Mantani A; Kurata A; Otagaki Y; Yamashita H; Yamawaki S
Transl Psychiatry; 2016 Mar; 6(3):e754. PubMed ID: 26954981
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology of treatment resistant depression among major depressive disorder patients in Israel.
Sharman Moser S; Chodick G; Gelerstein S; Barit Ben David N; Shalev V; Stein-Reisner O
BMC Psychiatry; 2022 Aug; 22(1):541. PubMed ID: 35948895
[TBL] [Abstract][Full Text] [Related]
28. Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation.
Lee CW; Chen YJ; Wu HF; Chung YJ; Lee YC; Li CT; Lin HC
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jul; 93():102-113. PubMed ID: 30940482
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
30. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
31. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
32. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
[TBL] [Abstract][Full Text] [Related]
33. The 5-HT
Papp M; Gruca P; Lason M; Litwa E; Newman-Tancredi A; Depoortère R
Psychopharmacology (Berl); 2023 Nov; 240(11):2419-2433. PubMed ID: 37310446
[TBL] [Abstract][Full Text] [Related]
34. Staging methods for treatment resistant depression. A systematic review.
Ruhé HG; van Rooijen G; Spijker J; Peeters FP; Schene AH
J Affect Disord; 2012 Mar; 137(1-3):35-45. PubMed ID: 21435727
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
[TBL] [Abstract][Full Text] [Related]
36. Treatment-Resistant Depression: Approaches to Treatment.
Kverno KS; Mangano E
J Psychosoc Nurs Ment Health Serv; 2021 Sep; 59(9):7-11. PubMed ID: 34459676
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response.
Aleksandrova LR; Wang YT; Phillips AG
Neurosci Biobehav Rev; 2019 Oct; 105():1-23. PubMed ID: 31336112
[TBL] [Abstract][Full Text] [Related]
38. Role of copper and ketamine in major depressive disorder - an update.
Słupski J; Słupska A; Szałach ŁP; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):520-523. PubMed ID: 31488784
[TBL] [Abstract][Full Text] [Related]
39. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression.
Wu B; Cai Q; Sheehan JJ; Benson C; Connolly N; Alphs L
PLoS One; 2019; 14(8):e0220763. PubMed ID: 31393922
[TBL] [Abstract][Full Text] [Related]
40. Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response.
Derosa S; Misztak P; Mingardi J; Mazzini G; Müller HK; Musazzi L
Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jan; 128():110871. PubMed ID: 37793481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
